Published in J Pain Res on December 17, 2008
Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br J Cancer (2001) 3.40
Breakthrough pain: definition, prevalence and characteristics. Pain (1990) 3.35
Understanding the experience of pain in terminally ill patients. Lancet (2001) 2.66
Breakthrough pain: characteristics and impact in patients with cancer pain. Pain (1999) 2.53
A validation study of the WHO method for cancer pain relief. Cancer (1987) 2.32
Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J Pain Symptom Manage (1997) 2.29
Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer (2002) 2.01
Breakthrough pain characteristics and syndromes in patients with cancer pain. An international survey. Palliat Med (2004) 1.71
New clinical-practice guidelines for the management of pain in patients with cancer. N Engl J Med (1994) 1.70
Clinical pharmacokinetics of fentanyl and its newer derivatives. Clin Pharmacokinet (1983) 1.45
Breakthrough cancer pain: a randomized trial comparing oral transmucosal fentanyl citrate (OTFC) and morphine sulfate immediate release (MSIR). Pain (2001) 1.43
A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain (2006) 1.38
EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology (1985) 1.28
Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain. J Support Oncol (2007) 1.18
Breakthrough pain in cancer patients: pathophysiology and treatment. Cancer Treat Rev (1998) 1.16
Prevalence and characteristics of breakthrough pain in opioid-treated patients with chronic noncancer pain. J Pain (2006) 1.16
Absolute and relative bioavailability of fentanyl buccal tablet and oral transmucosal fentanyl citrate. J Clin Pharmacol (2007) 1.14
Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin Pharmacokinet (2006) 1.11
Cancer breakthrough pain characteristics and responses to treatment at a VA medical center. Pain (2003) 1.11
Management of breakthrough pain in patients with cancer. Drugs (2008) 1.04
Pharmacokinetic properties of fentanyl effervescent buccal tablets: a phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 microg in healthy adult volunteers. Clin Ther (2006) 1.02
Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet. Expert Opin Pharmacother (2007) 1.02
Opioids for cancer breakthrough pain: a pilot study reporting patient assessment of time to meaningful pain relief. J Pain Symptom Manage (2008) 0.99
Alternative treatments of breakthrough pain in patients receiving spinal analgesics for cancer pain. J Pain Symptom Manage (2005) 0.96
Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin Pharmacokinet (2005) 0.96
Fentanyl buccal tablet (FBT) for relief of breakthrough pain in opioid-treated patients with chronic low back pain: a randomized, placebo-controlled study. Curr Med Res Opin (2007) 0.94
Characterization of breakthrough pain by hospice patients and their caregivers. J Pain Symptom Manage (1998) 0.94
Steady-state infusions of opioids in human. II. Concentration-effect relationships and therapeutic margins. Pain (1990) 0.93
Oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer: an open, multicentre, dose-titration and long-term use study. Palliat Med (2004) 0.92
Management of breakthrough pain due to cancer. Oncology (Williston Park) (1999) 0.90
Morphine, constipation and performance status in advanced cancer patients. Palliat Med (1999) 0.89
Absorption of fentanyl from fentanyl buccal tablet in cancer patients with or without oral mucositis: a pilot study. Clin Drug Investig (2007) 0.84
Mechanistic studies on effervescent-induced permeability enhancement. Pharm Res (1998) 0.84
Effervescent morphine results in faster relief of breakthrough pain in patients compared to immediate release morphine sulfate tablet. Pain Pract (2007) 0.82
[Permeation of active morphine-like substances at their sites of antinociceptive action in the brain as a function of their lipid-solubility following intravenous and intraventricular application]. Naunyn Schmiedebergs Arch Pharmakol (1970) 0.79
Fentanyl buccal tablets. Expert Opin Investig Drugs (2006) 0.79